• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Changing predictors of statin initiation in US women over two decades.二十多年来美国女性开始使用他汀类药物的预测因素发生了变化。
Pharmacoepidemiol Drug Saf. 2019 Mar;28(3):305-314. doi: 10.1002/pds.4704. Epub 2018 Dec 19.
2
Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.基于指南的他汀类药物适用情况、冠状动脉钙化与心血管事件
JAMA. 2015 Jul 14;314(2):134-41. doi: 10.1001/jama.2015.7515.
3
Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.2013年美国心脏病学会/美国心脏协会(ACC/AHA)胆固醇管理指南发布后两年内,美国一项大型医保计划中他汀类药物的起始使用模式
J Am Heart Assoc. 2017 May 4;6(5):e005205. doi: 10.1161/JAHA.116.005205.
4
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.2013年美国心脏病学会/美国心脏协会胆固醇指南对因急性冠状动脉综合征或中风住院患者高强度他汀类药物处方的影响。
Am Heart J. 2016 Nov;181:130-136. doi: 10.1016/j.ahj.2016.07.024. Epub 2016 Aug 26.
5
Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.美国心脏病学会/美国心脏协会(ACC/AHA)胆固醇指南对几种美国社区卫生中心网络中糖尿病患者心血管疾病预防中他汀类药物未充分利用的影响。
J Am Heart Assoc. 2017 Jul 3;6(7):e005627. doi: 10.1161/JAHA.117.005627.
6
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.低密度脂蛋白胆固醇≥190mg/dL患者降脂治疗使用情况的差异:来自国家心血管数据注册库 - 实践创新与临床卓越注册库的见解
Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004652. doi: 10.1161/CIRCOUTCOMES.118.004652.
7
Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry.2013 年 ACC/AHA 胆固醇指南对当代心血管实践中成年人的影响:来自 NCDR PINNACLE 注册研究的见解。
J Am Coll Cardiol. 2014 Dec 2;64(21):2183-92. doi: 10.1016/j.jacc.2014.08.041. Epub 2014 Nov 19.
8
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.美国杂合子家族性高胆固醇血症成人患者的治疗差距:来自CASCADE-FH注册研究的数据
Circ Cardiovasc Genet. 2016 Jun;9(3):240-9. doi: 10.1161/CIRCGENETICS.116.001381. Epub 2016 Mar 24.
9
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.在常规临床实践中,与其他他汀类药物相比,瑞舒伐他汀治疗的老年患者的低密度脂蛋白胆固醇(LDL-C)水平及LDL-C达标情况。
Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002.
10
Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.美国成年人他汀类药物使用情况及低密度脂蛋白胆固醇水平的趋势:2001年国家胆固醇教育计划指南的影响
Ann Pharmacother. 2008 Sep;42(9):1208-15. doi: 10.1345/aph.1L181. Epub 2008 Jul 22.

引用本文的文献

1
U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001-2002 and 2012-2013.美国疼痛患者,一个越来越容易遭受非医疗用大麻使用和大麻使用障碍影响的群体:2001-2002 年和 2012-2013 年。
Am J Psychiatry. 2020 Jul 1;177(7):611-618. doi: 10.1176/appi.ajp.2019.19030284. Epub 2020 Jan 22.

本文引用的文献

1
Statins for primary cardiovascular prevention in the elderly.他汀类药物用于老年人的原发性心血管疾病预防。
J Geriatr Cardiol. 2015 Jul;12(4):431-8. doi: 10.11909/j.issn.1671-5411.2015.04.016.
2
Duration of menopausal vasomotor symptoms over the menopause transition.绝经过渡期间绝经血管舒缩症状的持续时间。
JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063.
3
Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010.1999 - 2010年美国II型糖尿病患者中葡萄糖、血压和降脂药物的使用情况
Ann Epidemiol. 2014 Jul;24(7):516-21.e1. doi: 10.1016/j.annepidem.2014.05.001. Epub 2014 May 10.
4
Impact of the JUPITER trial on statin prescribing for primary prevention.JUPITER 试验对他汀类药物用于一级预防的处方影响。
Pharmacotherapy. 2014 Jan;34(1):9-18. doi: 10.1002/phar.1340. Epub 2013 Aug 12.
5
Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults.十余年来,社区居住的老年人群中降胆固醇药物的使用变化。
Ann Pharmacother. 2013 Jul-Aug;47(7-8):984-92. doi: 10.1345/aph.1S050. Epub 2013 Jun 18.
6
The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.表 2 谬误:呈现和解释混杂因素和修饰因素系数。
Am J Epidemiol. 2013 Feb 15;177(4):292-8. doi: 10.1093/aje/kws412. Epub 2013 Jan 30.
7
Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour.根据适应证和年龄使用他汀类药物:丹麦队列研究改变处方和购买行为。
Health Policy. 2012 Dec;108(2-3):216-27. doi: 10.1016/j.healthpol.2012.08.008. Epub 2012 Sep 10.
8
Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.观察性数据在比较有效性研究中的应用:他汀类药物随机试验与冠心病一级预防的模拟。
Stat Methods Med Res. 2013 Feb;22(1):70-96. doi: 10.1177/0962280211403603. Epub 2011 Oct 19.
9
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.瑞舒伐他汀用于 C-反应蛋白升高和低至中等低密度脂蛋白胆固醇水平的老年人一级预防:一项随机试验的探索性分析。
Ann Intern Med. 2010 Apr 20;152(8):488-96, W174. doi: 10.7326/0003-4819-152-8-201004200-00005.
10
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.他汀类药物与新发糖尿病风险:随机他汀类药物试验的协作荟萃分析。
Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16.

二十多年来美国女性开始使用他汀类药物的预测因素发生了变化。

Changing predictors of statin initiation in US women over two decades.

机构信息

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

RTI Health Solutions, Research Triangle Park, NC, USA.

出版信息

Pharmacoepidemiol Drug Saf. 2019 Mar;28(3):305-314. doi: 10.1002/pds.4704. Epub 2018 Dec 19.

DOI:10.1002/pds.4704
PMID:30565779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7147936/
Abstract

PURPOSE

To describe changing roles of predictors of statin initiation before and after incident coronary heart disease, and before and after publication of National Cholesterol Education Program Adult Treatment Panel-III (ATP-III) guidelines in a cohort of US women.

METHODS

We identified 34 382 women enrolled into the Women's Health Study from 1993 to 1995 and followed up until 2012. Proportions of previous nonusers initiating statins were described over time. We used multivariable linear regression models to estimate adjusted initiation proportion differences (IPDs) for initiation overall, separately before and after incident coronary heart disease, and separately for ATP-II and ATP-III time periods.

RESULTS

Key predictors of initiation overall were self-reported total cholesterol, and previous incident coronary heart disease, cerebrovascular disease, and diabetes. Adjusted IPDs (percentage) for total cholesterol > 240 vs <200 mg/dL were 7.5 (95% confidence interval [CI], 7.0-8.0) and 9.3 (95% CI, 8.7-9.9) during ATP-II and ATP-III time periods, respectively. Adjusted IPDs in women with diabetes were 7.0 (95% CI, 6.3-7.8) and 11.9 (95% CI, 6.7-17.0) for primary and secondary prevention, respectively, and 3.1 (95% CI, 2.1-4.0) and 9.2 (95% CI 8.2-10.2) for before and after ATP-III, respectively.

CONCLUSIONS

Secular trends reflected evolution toward risk factor-based treatment indications for statin initiation with increased initiation among diabetics and women with normal and borderline cholesterol. The role of serum cholesterol changed over time, though the character was scale (multiplicative vs additive) dependent. In pharmacoepidemiologic studies of statins, strength of confounding by important variables sometimes unmeasured in claims data, such as cholesterol level, may be calendar time dependent.

摘要

目的

描述在美国女性队列中,在发生冠心病之前和之后,以及在国家胆固醇教育计划成人治疗专家组-III(ATP-III)指南发布之前和之后,预测他汀类药物起始的角色变化。

方法

我们从 1993 年至 1995 年入组了妇女健康研究中的 34382 名女性,并随访至 2012 年。描述了过去未使用者开始使用他汀类药物的比例随时间的变化。我们使用多变量线性回归模型估计了总体起始、在发生冠心病之前和之后以及在 ATP-II 和 ATP-III 时间段内的起始的调整起始比例差异(IPD)。

结果

总体起始的主要预测因素是自我报告的总胆固醇,以及以前发生的冠心病、脑血管病和糖尿病。总胆固醇>240 与<200mg/dL 相比,在 ATP-II 和 ATP-III 时间段内的调整 IPD(百分比)分别为 7.5(95%置信区间[CI],7.0-8.0)和 9.3(95%CI,8.7-9.9)。糖尿病女性的调整 IPD 分别为一级和二级预防的 7.0(95%CI,6.3-7.8)和 11.9(95%CI,6.7-17.0),以及 ATP-III 前后的 3.1(95%CI,2.1-4.0)和 9.2(95%CI,8.2-10.2)。

结论

随着基于危险因素的他汀类药物起始治疗指征的演变,他汀类药物起始的趋势呈上升趋势,包括糖尿病患者和胆固醇正常或边缘升高的女性。血清胆固醇的作用随时间而变化,但特征取决于比例(乘法与加法)。在他汀类药物的药物流行病学研究中,在索赔数据中有时未测量到的重要变量(如胆固醇水平)的混杂强度可能与日历时间有关。